Abstract. Leukemia-inhibitory factor (LIF) and Angiopoietin-2 (Ang-2) are important factors in fertility. In the present study, it was investigated whether Bu Shen Huo Xue Decoction (BSHXD) prevents controlled ovarian hyperstimulation (COH) treatment-induced changes in endometrial LIF and Ang-2 expression and whether it has an effect on the number of implantation sites and live births in rats. Uteri were collected on day (D) 3, 4 and 5 of pregnancy, and LIF and Ang-2 protein and mRNA expression were detected using western blot analysis and quantitative polymerase chain reaction. On pregnancy D10, the average number of implantation sites was observed. The number of live births from each group was recorded. The results indicated that BSHXD treatment markedly increased the number of live births by restoring endometrial LIF expression and the implantation capacity in the COH rat model. In addition, no association was identified between LIF and Ang-2 expression. Therefore, this suggests that BSHXD may be useful for female reproduction.

Introduction

Implantation is a critical step during normal pregnancy. The implantation process occurs after 4-6 days of pregnancy in rats (plug presented day = gestation day 1) (1), and a similar phenomenon also occurs in humans between days luteinizing hormone (LH)+6 and LH+8 (2). Successful implantation requires a receptive endometrium, a normal embryo at the blastocyst developmental stage and a synchronized dialogue between maternal and embryonic tissues (3).

A prerequisite for implantation is increased endometrial angiogenesis and vascular remodeling at the implantation site. Leukemia-inhibitory factor (LIF) is a well-characterized cellular factor that is a promising candidate as an endometrial receptivity biomarker in mice (4) and humans (5,6). LIF knock-out female mice are infertile, and implantation of the embryo does not occur (7). LIF has a role in the adhesive and invasive phases of implantation (8). Angiopoietin-2 (Ang-2) destabilizes the quiescent endothelium and primes it to respond to exogenous stimuli, thereby modulating angiogenic cytokine activity (9,10). Ang-2 is expressed in the peri-implantation endometrium in a spatiotemporal manner and participates in angiogenesis and the vascular remodeling process (11). Although LIF and Ang-2 are essential for normal blastocyst implantation, it is not yet clear whether there is an association between LIF and Ang-2.

The controlled ovarian hyperstimulation (COH) with gonadotropin-releasing hormone agonist (GnRHa) long protocol is an important approach in IVF. COH results in high-quality embryos; however, even with ongoing advances, implantation rates are still relatively low (12). A number of studies have demonstrated that COH may directly change endometrial characteristics compared with those of the natural cycle (13-15), and these differences may alter endometrial receptivity (16). Furthermore, high serum estradiol levels or other hormonal alterations that result from COH may indirectly adversely affect implantation (17,18).

Although the current understanding of implantation has increased, therapeutic options remain limited (19). Further study is required to investigate clinical treatment options for infertility patients with implantation failure. In China, traditional Chinese medicine (TCM) harmonizes the endocrine environment to assist with assisted reproductive technology (20-22), and integrating the principles and knowledge from TCM may be useful in clinical practice to provide better strategies for treating infertility (23). Therefore, in the present study, Bu Shen Huo Xue Decoction (BSHXD) was established to aid in preparing the endometrium for implantation (Table I).

In the present study, endometrial LIF and Ang-2 protein and mRNA expression was investigated, and the number of implantation sites and live births in a COH rat model were determined to elucidate the side-effects of COH on fertility. It was hypothesized that BSHXD can ameliorate these side-effects.
and improve endometrial receptivity and pregnancy outcome. The results may therefore provide evidence to support the use of BSHXD in assisted reproduction.

**Materials and methods**

*(Ethics statement.)* All the experimental protocols were approved by the Ethics Committee of the Beijing University of Chinese Medicine Animal Care and Use Committee (no. 2012-087-R; Beijing, China).

**BSHXD preparation.** The drugs present in BSHXD were obtained from the Pharmacy Department of Dongfang Hospital of Beijing University of Chinese Medicine (Beijing, China). The quality of the raw herbs was controlled according to the requirements of the Pharmacopoeia of the People’s Republic of China. An aqueous extract of BSHXD was prepared in accordance with the following procedure. In brief, the components (as shown in Table I) were mixed in proportion and were macerated for 1 h with 8 volumes of distilled water and then decocted for 2 h. The cooled extract was filtered. The extraction procedure was repeated twice. The extracts were then combined and concentrated by boiling to a final volume of 100 ml (4.12 g/ml). This dilution was used in the following preliminary experiments in a range of concentrations (between 1.03 and 4.12 g/ml).

**Treatment.** Female Sprague Dawley rat virgins aged 7-8 weeks old (weighing 210-220 g) were maintained in the laboratory on a 12 h light, 12 h dark regimen with free access to water and a standard diet. The estrous stage was identified by vaginal smear. Only female rats with regular cycles were used. The rats were subjected to the same GnRHa long protocol as the COH group. In brief, a GnRH agonist, the drugs present in BSHXD were administered in the laboratory on a 12 h light, 12 h dark regimen with free access to water and a standard diet. The estrous stage was identified by vaginal smear. Only female rats with regular cycles were used. The rats were subjected to the same GnRHa long protocol as the COH group. In brief, a GnRH agonist (Diphereline; Ipsen Pharma Biotech, Signes, France) was injected intraperitoneally at 1.5 µg/100 g body weight/day between the third and ninth day of estrous followed by saline injections at the same time and volume as the COH group. The female rats were housed overnight with males (1:1) following hCG or saline administration. Successful mating was assessed daily by the presence of a vaginal plug. The day that the plug was first observed was designated as day 0 of gestation (D0).

On each of D3, D4 and D5, 6 rats were sacrificed from each group. The uterus were removed without excess fat and connective tissue and the whole sample was stored at -80°C until protein and mRNA extraction.

| Component | Ratio |
|-----------|-------|
| (1) Sheng Di [Rehmannia glutinosa (Gaertn.) Libosch., root] | 15 |
| (2) Dan Shen [Salviae miltiorrhizae Bge., root] | 10 |
| (3) Dang Gui [Angelica sinensis (Oliv.) Diels., root] | 12 |
| (4) Chuan Duan [Dipsacus asperoides C. Y. Cheng et T. M. Ai., root] | 15 |
| (5) Du Zhong [Eucommia ulmoides Oliv., cortex] | 12 |
| (6) Shan Yao [Dioscorea opposita Thunb., rhizome] | 15 |
| (7) Mei Gui-hua [Rosa rugosa Thunb., flower] | 6 |
| (8) Chuan Xiong [Ligusticum chuanxiong Hort., rhizome] | 6 |
| (9) Yi Yi-ren [Coix lacryma-jobi L. var. ma-yuen (Roman.) Stapf., seed] | 12 |

**Table I. Bu Shen Huo Xue Decoction (BSHXD) composition.**

**Western blot analysis.** The uterus was sectioned, and slices were incubated and lysed in RIPA lysis buffer (C1053; Applied Technologies, Beijing, China) supplemented with protease inhibitor (P1265; Applied Technologies). The protein concentration was quantified with bicinchoninic acid (P1511; Applied Technologies). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis was performed using a 10% polyacrylamide gel, and the samples were transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA, USA). Membranes were blotted with anti-LIF (sc-1336; Santa Cruz Biotechnology, Heidelberg, Germany) or anti-Ang-2 (AP23297PU-N; Acris Antibodies, Herford, Germany) primary antibodies at a 1:1,000 dilution and 4°C overnight. Following incubation, the membranes were washed 3 times with Tris-buffered saline and Tween 20 buffer and then incubated with the secondary antibodies (P1308, P1309; Applied Technologies) at a 1:10,000 dilution at room temperature for 1 h. The blots were visualized using the Super ECL Plus detection reagent (P1010; Applied Technologies). The enhanced chemiluminescence signals were detected using Quantity One software (Bio-Rad). GAPDH (blotted with ab8245; Abcam, Cambridge, UK) was used as an internal control to validate the quantity of protein loaded onto the gel.

**qPCR analysis.** LIF and Ang-2 gene expression was measured using qPCR. Total RNA was extracted from the uteri of the control, COH, BSHXD and COH+BSHXD rats using TRIzol (Invitrogen Life Technologies, Carlsbad, CA, USA), in accordance with the manufacturer’s instructions. The RNA was thawed on ice and quantified spectrophotometrically; the quality was assessed using sodium dodecyl sulfate-agarose gel electrophoresis. Reverse transcription was performed with 8 µl total RNA per 20 µl reaction using a standard cDNA synthesis
Western blot analysis. Endometrial LIF and Ang-2 protein expression levels during implantation were determined using western blot analysis. The LIF and Ang-2 protein expression levels were normalized against those of GAPDH (Fig. 1). The LIF protein expression levels were found to be increased during the implantation period in the four groups (Fig. 2). However, COH treatment significantly reduced the level of LIF protein expression in the COH group compared with that in the other groups. No significant difference was identified between the LIF protein levels in the control and the COH+BSHXD groups on D4 and D5. Compared with the control and the COH+BSHXD treatment, BSHXD treatment significantly increased the level of LIF protein expression in the BSHXD group. However, no significant differences in the level of Ang-2 protein expression were observed from D3 to D5.

qPCR. To verify the changes in expression levels, LIF and Ang-2 transcript levels were measured using qPCR. The differences in the qPCR results were statistically significant, and substantial differences in expression were observed using western blot analysis. LIF and Ang-2 mRNA were expressed in the rat endometrium during implantation. LIF mRNA expression levels were increased from D3 to D5 (Fig. 3). COH treatment significantly reduced the LIF mRNA expression levels compared with those in the control, BSHXD and COH+BSHXD groups, and the BSHXD group had significantly increased LIF mRNA expression levels compared with the control and COH+BSHXD groups. However, no significant differences were identified in Ang-2 mRNA expression levels from D3 to D5 (Fig. 4).

Number of implantation sites and live births. The effects of COH and BSHXD on the number of implantation sites and live births are summarized in Table III. The number of implantation sites and live births in each group.

| Variables         | Control       | COH           | BSHXD         | COH+BSHXD     |
|-------------------|---------------|---------------|---------------|---------------|
| Implantation sites| 8.67±1.93     | 3.60±0.51*a   | 9.14±1.18     | 7.83±0.48     |
| Live births       | 9.00±1.90     | 3.17±0.40*a   | 9.50±0.56     | 7.33±0.49     |

COH, GnRHa long protocol-stimulated rats; BSHXD, rats that received BSHXD treatment; COH+BSHXD, GnRHa long protocol-stimulated rats that received BSHXD treatment. Values are expressed as the mean ± standard error of the mean (n=6 in each group). *P<0.05, versus all the groups. COH, controlled ovarian hyperstimulation; GnRHa, gonadotropin-releasing hormone agonist; BSHXD, Bu Shen Huo Xue Decoction.
of implantation sites and live births in the COH group was significantly lower compared with those in the other groups. No significant difference was identified among the control, BSHXD and COH+BSHXD groups; however, the implantation site and live-birth number was highest in the BSHXD group.

**Discussion**

The aim of the present study was to investigated the effect of BSHXD in a COH rat model during the implantation window using western blot and qPCR analyses and by measuring the average number of implantation sites and live births.
In numerous mammalian species, including mice, humans and sheep, uterine LIF expression is upregulated during the onset of embryo implantation (24), suggesting that LIF may be of general significance to implantation in mammals. Previous studies on early murine pregnancy have demonstrated that LIF expression levels are highest in the uterus between the fourth and fifth day of pregnancy (25). These data are consistent with the results from the present study that demonstrated that LIF expression increased during implantation in the four groups and peaked on D5. A role for LIF in implantation regulation and embryonic development was proposed. The observation that recombinant LIF inhibits murine embryonic stem cell differentiation (26,27) indicates that LIF may have a role in early embryonic growth and development. LIF mRNA is expressed in murine embryos from the fertilized egg to the blastocyst stage (28,29). These data likely explain why lower LIF protein and mRNA expression in the COH group was associated with lower implantation site numbers. Furthermore, LIF may also be important during placentation and subsequent fetal development. A potential role for LIF in placentation was first suggested when the LIF receptor (LIFR) was cloned from a human placental cDNA library (30), which was further strengthened by a study demonstrating that normal placentation was disrupted in LIFR<sup>−/−</sup> mouse embryos (31). A possible explanation for the lower numbers of live births in the COH group in the present study is that the establishment of decidualization and placentation requires LIF; however, COH treatment significantly disturbed LIF expression. This indicates that LIF may have an important role in pregnancy establishment.

The other major finding of the present study was that there were no significant differences in Ang‑2 expression among the four groups. Angiopoietins are a family of growth factors that promote vessel maturation and remodeling (32,33), which are important processes during implantation (34-36). Ang-2 causes loosening of cell-matrix and cell-to-cell contacts, which allows access to angiogenic inducers (37). Therefore, Ang-2 expression may promote angiogenesis (38). Furthermore, Ang-2 is selectively expressed in the ovary, uterus and placenta of mice and humans (32). Thus, it was hypothesized in the present study that Ang-2 expression would demonstrate a similar increase to LIF during implantation. However, this association was not observed. The lack of a difference in endometrial Ang-2 expression from D3 to D5 is that angiogenic mechanisms during implantation may not require Ang-2. In a previous study, Ang-2 expression levels were determined

![Graph A](image1.png)
![Graph B](image2.png)
![Graph C](image3.png)
![Graph D](image4.png)
using in situ hybridization and it was demonstrated that Ang-2 was expressed at low levels between the first and fifth days of pregnancy (peri-implantation) and was then expressed at higher levels from the sixth to seventh day in mice (11). These results clearly demonstrate that Ang-2 may not be a dominant angiogenic factor during the early stages of pregnancy. The results of the present study support the theory that maternal regulation of endometrial angiogenesis prior to implantation is different from the regulation that occurs once the embryo has implanted (39).

It has been hypothesized that using COH with GnRHa in a long protocol to induce multifollicular development may also affect endometrial receptivity (40,41). The endometrium undergoes a morphological advancement prior to implantation, and it is not surprising that a side-effect of COH is the regulation of supraphysiologically levels of steroid hormones and paracrine mediators produced and received by the endometrium. Genomic analyses of human endometrial receptivity have been previously performed (42,43), and these analyses demonstrate that numerous genes are aberrantly expressed in the COH endometrium, and the expression levels are similar to those in a non-receptive endometrium (44). These previous studies highlight the necessity for modifying COH treatment to achieve an endometrium that resembles that of the natural endometrium cycle morphologically and functionally, which is likely to improve pregnancy outcomes. Therefore, BSHXD was used along with COH treatment to promote the recovery of the impaired endometrium in rats. In a previous study, the authors of the present study demonstrated the effects of BSHXD on endometrial morphology and LIF expression in non-pregnant rats (45). The results from the present study, including increased LIF expression, and restored implantation site and live-birth numbers in the COH+BSHXD group, suggest that BSHXD treatment may be a clinical option for patients with an impaired endometrium following COH treatment. TCM uses a holistic and synergistic approach to restore homeostasis (46); however, TCM does not translate the normal state into a super-normal one, which accounts for a lack of significant differences between the control and BSHXD groups.

In conclusion, it was demonstrated that: i) COH treatment significantly decreased LIF protein and mRNA expression levels and the number of implantation sites and live births in rats compared with those in the natural cycle; ii) integrating BSHXD and COH treatment restores LIF expression and significantly increases the probability of implantation and the number of live births; iii) no significant differences in LIF expression or the average number of implantation sites and live births were observed among the control, BSHXD and COH+BSHXD groups; iv) LIF and Ang-2 were expressed in mature female rat endometrium during the implantation window; however, no association was found between LIF and Ang-2 expression. The results from the present study provide novel insights into a TCM approach for infertility treatment and assisted reproductive technology. However, further clinical studies are required to confirm the proposed approach.

Acknowledgements

This study was supported by the Natural Science Foundation of China (no. 81173292).

References

1. Psychoyos A: Hormonal control of ovoimplantation. Vitam Horm 31: 201-256, 1973.
2. Nikas G: Endometrial receptivity: changes in cell-surface morphology. Semin Reprod Med 18: 229-235, 2000.
3. Simón C, Martín JC and Pellicer A: Paracrine regulators of implantation. Baillieres Best Pract Res Clin Obstet Gynaecol 14: 815-826, 2000.
4. Escary JL, Perreau J, Daménil D, Ezine S and Brillet P: Leukaemia inhibitory factor is necessary for maintenance of haematoepoietic stem cells and thymocyte stimulation. 363: 361-364, 1993.
5. Cavagna M and Munteșe JC: Biomarkers of endometrial receptivity - a review. Placenta 24 (Suppl B): S39-S47, 2003.
6. Hoozemans DA, Schats R, Lambalk CB, Homburg R and Hompes PG: Human embryo implantation: current knowledge and clinical implications in assisted reproductive technology. Reprod Biomed Online 9: 692-715, 2004.
7. Stewart CL, Kaspar P, Brunet LJ, et al: Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor. Nature 359: 76-79, 1992.
8. Dimitriadis E, Nie G, Hannan NJ, Paiva P and Salamonsen LA: Local regulation of implantation at the human fetal-maternal interface. Int J Dev Biol 54: 313-322, 2010.
9. Fiedler U, Reiss Y, Scharfenbecker M, et al: Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 12: 235-239, 2006.
10. Maisonnier Pierre C., Suri C., Jones P.F., et al: Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277: 55-60, 1997.
11. Matsumoto H, Ma WG, Daikoku T, et al: Cyclooxygenase-2 differentially directs uterine angiogenesis during implantation in mice. J Biol Chem 277: 29260-29267, 2002.
12. de Mouzon J, Goossens V, Bhattarcharya S, et al: European IVF-monitoring (EIM) Consortium, for the European Society of Human Reproduction and Embryology (ESHRE): Assisted reproductive technology in Europe, 2006: results generated from European registries by ESHRE. Hum Reprod 25: 1851-1862, 2010.
13. Papanikolaou EG, Bourgain C, Kolibianakis E, Tourneur H and Devroey P: Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes. Hum Reprod 20: 1541-1547, 2005.
14. Fauser BC and Devroey P: Reproductive biology and IVF: ovarian stimulation and luteal phase consequences. Trends Endocrinol Metab 14: 236-242, 2003.
15. Saada P, Boonstartan R, Slater CC, Tourgeman DE, Stanczyk FZ and Paulson RJ: Accelerated endometrial maturation in the luteal phase of cycles utilizing controlled ovarian hyperstimulation: impact of gonadotropin-releasing hormone agonists versus antagonists. Fertil Steril 82: 167-171, 2004.
16. Kolibianakis E, Bourgain C, Albano C, et al: Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin-releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up. Fertil Steril 78: 1025-1029, 2002.
17. Pellicer A, Valbuena D, Cano F, Remohi J and Simón C: Lower implantation rates in high responders: evidence for an altered endocrine milieu during the preimplantation period. Fertil Steril 65: 1190-1195, 1996.
18. Check JH, Choe JK, Katsoff D, Summers-Chase D and Wilson C: Controlled ovarian hyperstimulation adversely affects implantation following in vitro fertilization-embryo transfer. J Assist Reprod Genet 16: 416-420, 1999.
19. Toth B, Würfel W, Gerner M, Hlavin L and Diczfalusy E: Local regulation of implantation at the human fetal-maternal interface - are there diagnostic and therapeutic options? J Reprod Immunol 90: 117-123, 2011.
20. Wu XT, Fu P and Wang YP: Use of traditional Chinese medicine in assisted reproductive technology. Chinese Archives of Traditional Chinese Medicine 27: 120-123, 2009 (In Chinese).
21. Zhang JW, Lian F, Zhepe H and Yan H: Effect of Erzhi Tiangui granules (traditional Chinese medicine) on follicular fluid interleukin-1β, interleukin-6 concentration and embryo quality in patients undergoing controlled ovarian hyperstimulation. Reprod Contracept 27: 714-717, 2007 (In Chinese).
22. Lian F, Teng YL, Zhang JW, et al: Clinical study on Erzhi Tiangui granules combined with in vitro fertilization-embryo transplant for treatment of 61 cases of infertility. J Tradit Chin Med 47: 439-441, 2006 (In Chinese).
23. Huang ST and Chen AP: Traditional Chinese medicine and infertility. Curr Opin Obstet Gynecol 20: 211-215, 2008.
24. Kimber SJ: Leukaemia inhibitory factor in implantation and uterine biology. Reproduction 130: 131-145, 2005.
25. Bhatt H, Brunet LJ and Stewart CL: Uterine expression of leukemia inhibitory factor coincides with the onset of blastocyst implantation. Proc Natl Acad Sci USA 88: 11408-11412, 1991.
26. Smith AG, Heath JK, Donaldson DD, et al: Inhibition of pluripotential embryonic stem cell differentiation by. Nature 336: 688-690, 1988.
27. Williams RL, Hilton DJ, Pease S, et al: Myeloid leukemia inhibitory factor maintains the developmental potential of embryonic stem cells. Nature 336: 684-687, 1988.
28. Conquest F and Brûlet P: Developmental expression of myeloid leukemia inhibitory factor gene in preimplantation blastocysts and in extraembryonic tissue of mouse embryos. Mol Cell Biol 10: 3801-3805, 1990.
29. Murray R, Lee F and Chiu CP: The genes for leukemia inhibitory factor and interleukin-6 are expressed in mouse blastocysts prior to the onset of hemopoiesis. Mol Cell Biol 10: 4953-4956, 1990.
30. Gearing DP, Thut CJ, Vandebos T, et al: Leukemia inhibitory factor receptor is structurally related to the IL-6 signal transducer, gp130. EMBO J 10: 2839-2848, 1991.
31. Ware CB, Horowitz MC, Renshaw BR, et al: Targeted disruption of the low-affinity leukemia inhibitory factor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death. Development 121: 1283-1299, 1995.
32. Gale NW and Yancopoulos GD: Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 13: 1055-1066, 1999.
33. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ and Holash J: Vascular-specific growth factors and blood vessel formation. Nature 407: 242-248, 2000.
34. Charnock-Jones DS, Kaufmann P and Mayhew TM: Aspects of human fetoplacental vasculogenesis and angiogenesis. I. Molecular regulation. Placenta 25: 103-113, 2004.
35. Kaufmann P, Mayhew TM and Charnock-Jones DS: Aspects of human fetoplacental vasculogenesis and angiogenesis. II. Changes during normal pregnancy. Placenta 25: 114-126, 2004.
36. Red-Horse K, Drake P and Fisher S: Human pregnancy: the role of chemokine networks at the fetal-maternal interface. Expert Rev Mol Med 6: 1-14, 2004.
37. Hur SE, Lee JY, Moon HS and Chung HW: Angiopoietin-1, angiopoietin-2 and Tie-2 expression in eutopic endometrium in advanced endometriosis. Mol Hum Reprod 12: 421-426, 2006.
38. Hanahan D: Signaling vascular morphogenesis and maintenance. Science 277: 45-50, 1997.
39. Rabbani ML and Rogers PA: Role of vascular endothelial growth factor in endometrial vascular events before implantation in rats. Reproduction 122: 85-90, 2001.
40. Simón C, Cano F, Valbuena D, Remohí J and Pellicer A: Implantation: Clinical evidence for a detrimental effect on uterine receptivity of high serum oestradiol concentrations in high and normal responder patients. Hum Reprod 10: 2432-2437, 1995.
41. Carson DD, Lagow E, Thathiah A, et al: Changes in gene expression during the early to mid-luteal (receptive phase) transition in human endometrium detected by high-density microarray screening. Mol Hum Reprod 8: 871-879, 2002.
42. Kao LC, Tulac S, Lobo S, et al: Global gene profiling in human endometrium during the window of implantation. Endocrinology 143: 2119-2138, 2002.
43. Horcajadas JÁ, Riesewijk A, Polman J, et al: Effect of controlled ovarian hyperstimulation in IVF on endometrial gene expression profiles. Mol Hum Reprod 11: 195-205, 2005.
44. Gong X, Yu Y, Tong Q, Ren Y and Jin Z: Effects of ‘Bu Shen Huo Xue Decoction’ on the endometrial morphology and expression of leukaemia inhibitory factor in the rat uterus during the oestrous cycle. Evid Based Complement Alternat Med 2013: 496036, 2013.
45. Efferth T, Li PC, Konkimutha VSB and Kaina B: From traditional Chinese medicine to rational cancer therapy. Trends Mol Med 13: 353-361, 2007.